Brentuximab Vedotin for Relapsed/Refractory CD30-positive Non-Hodgkin Lymphomas
Clinical trial NCT02280785 · COMPLETED
Trial details
- NCT number
- NCT02280785
- Sponsor
- Samsung Medical Center
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2014-11-01
- Primary completion
- 2017-12-01
- Enrollment
- 33
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.